IMProving Executive Function Study

PHASE4CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

September 22, 2017

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
Cognitive ImpairmentRRSO
Interventions
DRUG

Lisdexamfetamine

Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause.

DRUG

Placebo oral capsule

The placebo capsule will be filled with microcellulose.

Trial Locations (1)

19104

3535 Market Street, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT03187353 - IMProving Executive Function Study | Biotech Hunter | Biotech Hunter